Trial · NCT07884305
Transcutaneous Genital Nerves Stimulation for the Treatment of Refractory Chronic Pelvic and Genital Pain in Women.
NCT07884305, Not applicable, Not yet recruiting, Prof. Dr. med. Marc Possover
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Transcutaneous Genital Nerves Stimulation for the Treatment of Refractory Chronic Pelvic and Genital Pain in Women. Trials, record NCT07884305. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884305
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Transcutaneous Genital Nerves Stimulation for the Treatment of Refractory Chronic Pelvic and Genital Pain in Women.
- NCT number
- NCT07884305
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Prof. Dr. med. Marc Possover
- Conditions
- Refractory Visceral Pelvic Pain, Refractory Genital Pain
- Interventions
- Transcutaneous Genital Nerves Stimulation
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Genital and/or Visceral Pelvic Pain Intensity | Baseline and 12 weeks after initiation of treatment | Change in patient-reported pain intensity from baseline, assessed using a 0-10 Visual Analog Scale (VAS), where 0 represents no pain and 10 represents the worst imaginable pain. Genital and visceral pelvic pain will be assessed separately, according to the symptoms present at baseline. Higher scores indicate greater pain intensity. A reduction in score indicates improvement. |
| Secondary | Patient Global Impression of Improvment (PGI-I) | Baseline and 12 weeks after initiation of treatment | Patient-reported overall improvement assessed using the 7-point PGI-I scale, ranging from 1 (very much better) to 7 (very much worse). |
| Secondary | Change in Sitting Tolerance | Baseline and 12 weeks after initiation of treatment | Change in the maximum duration of sitting tolerated before pain becomes intolerable, measured in minutes and compared with baseline. |
| Secondary | Change in Health-Related Quality of Life assessed by the EQ-5D-5L Visual Analogue Scale (EA VAS) | Baseline and 12 weeks after initiation of treatment | Change from baseline in self-reported health status assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L), specifically its visual analogue scale (EQ VAS). The EQ VAS ranges from 0 (worst imaginable health) to 100 (best imaginable health). Higher scores indicate better self-reported health status. The outcome is the change in EQ VAS score from baseline to 12 weeks. |
| Secondary | Proportion of Participants Achieving at Least 50% Pain Reduction | Baseline and 12 weeks after initiation of treatment | Percentage of participants achieving a reduction of at least 50% in their prespecified target pain score compared with baseline, measured on a 0-10 pain scale. |
| Secondary | Incidence of Treatment-Related Adverse Events | Baseline and 12 weeks after initiation of treatment | Number and proportion of participants experiencing treatment-related adverse events, including skin irritation, discomfort during stimulation, or worsening of pelvic or genital pain. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884305
GET https://conductscience.org/api/trials/v1/NCT07884305/registered